{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T16:42:48Z","timestamp":1701880968074},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background Non-alcoholic fatty liver disease (NAFLD) affects more\n      than 18 million individuals in Germany. Real-world data help to better characterize the\n      natural history of disease and standard of care.<\/jats:p><jats:p>\n          Methods The German NAFLD-Registry is a prospective\n      non-interventional study initiated by the German Liver Foundation and aims to describe\n      clinical characteristics and observe outcomes in patients with NAFLD recruited in secondary\n      and tertiary care.<\/jats:p><jats:p>\n          Results From this ongoing study, baseline data of the first 501\n      patients (mean age 54 years, 48% women) were analysed. 13 % of the study population had a high\n      risk for advanced fibrosis (FIB-4 \u22652.67), approximately one-third had a liver stiffness value\n      \u22659.6kPa measured by transient elastography, and the clinical diagnosis of liver cirrhosis was\n      present in 10%. Typical comorbidities were more prevalent in high risk as compared to low risk\n      patients (FIB-4 &lt;1.3) including arterial hypertension (85 vs. 42%), hypercholesterolemia\n      (39 vs. 16%), and type 2 diabetes mellitus (T2DM) (69 vs. 26%). Patients with T2DM (192\/501)\n      had a higher NAFLD disease burden as shown by liver stiffness values \u22659.6 kPa (51%) and\n      clinical diagnosis of cirrhosis (20%). Statins were used in 22% of the main population, while\n      in diabetic patients, metformin, GLP-1 agonists, and SGLT2 inhibitors were used in 65, 17, and\n      17%, respectively. Uptake of life-style interventions such as physical exercise or nutritional\n      counselling was generally low.<\/jats:p><jats:p>\n          Conclusion First data of the German NAFLD registry show that\n      approximately every 10th patient has advanced NAFLD, highlights T2DM patients as a high-risk\n      group and gives insights in the use of comedication and life-style interventions in secondary\n      and tertiary care.<\/jats:p>","DOI":"10.1055\/a-1986-7676","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T23:57:16Z","timestamp":1673308636000},"page":"60-70","source":"Crossref","is-referenced-by-count":3,"title":["Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany \u2013 First data from the German NAFLD-Registry"],"prefix":"10.1055","volume":"61","author":[{"given":"Andreas","family":"Geier","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}]},{"given":"Monika","family":"Rau","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}]},{"given":"Anita","family":"Pathil-Warth","sequence":"additional","affiliation":[{"name":"Goethe University Hospital, Frankfurt am Main, Germany"}]},{"given":"Manfred","family":"von der Ohe","sequence":"additional","affiliation":[{"name":"Gastroenterologische Studiengesellschaft Herne, Herne, Germany"}]},{"given":"J\u00f6rn","family":"Schattenberg","sequence":"additional","affiliation":[{"name":"University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}]},{"given":"Nektarios","family":"Dikopoulos","sequence":"additional","affiliation":[{"name":"Praxis Ludwig & Dikopoulos, Dornstadt, Germany"},{"name":"Klinik f\u00fcr Innere Medizin 1, Ulm University Medical Center, Ulm, Germany"}]},{"given":"Kerstin","family":"Stein","sequence":"additional","affiliation":[{"name":"Hepatologie Magdeburg, Magdeburg, Germany"}]},{"given":"Yvonne","family":"Serfert","sequence":"additional","affiliation":[{"name":"Leberstiftungs-GmbH Deutschland, Hannover, Germany"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[{"name":"University Hospital Leipzig, Leipzig, Germany"}]},{"given":"Peter","family":"Buggisch","sequence":"additional","affiliation":[{"name":"ifi-Institute for Interdisciplinary Medicine, Hamburg, Germany"}]},{"given":"M\u00fcnevver","family":"Demir","sequence":"additional","affiliation":[{"name":"Charit\u00e9 University Medicine, Campus Virchow Clinic, Berlin, Germany"}]},{"given":"Elke","family":"Roeb","sequence":"additional","affiliation":[{"name":"Justus Liebig-University Giessen and University Hospital, Giessen, Germany"}]},{"given":"Bianka","family":"Wiebner","sequence":"additional","affiliation":[{"name":"Deutsche Leberstiftung, Hannover, Germany"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Hannover, Germany"},{"name":"Leberstiftungs-GmbH Deutschland, Hannover, Germany"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[{"name":"Goethe University Hospital, Frankfurt am Main, Germany"}]},{"given":"Wolf P.","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Gastroenterologie am Bayerischen Platz, Berlin, Germany"}]}],"member":"194","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and\n          prevention","volume":"15","author":"Z Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic\n          Steatohepatitis","volume":"69","author":"Z Younossi","year":"2019","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.3390\/cancers12113182","article-title":"Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma\n          and Its Prognostic Role","volume":"12","author":"S De Lorenzo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain,\n          United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"C Estes","year":"2018","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep4.1899","article-title":"Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study\n          in Germany","volume":"6","author":"Y Huber","year":"2022","journal-title":"Hepatol Commun"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/lt.24461","article-title":"Liver transplantation in Germany","volume":"22","author":"F Tacke","year":"2016","journal-title":"Liver transplantation: official publication of the American Association for the\n          Study of Liver Diseases and the International Liver Transplantation Society"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.21037\/atm-20-7179","article-title":"Healthcare resource utilization and costs among nonalcoholic fatty liver disease\n          patients in Germany","volume":"9","author":"A Canbay","year":"2021","journal-title":"Ann Transl Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/apt.14976","article-title":"Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease\n          in Germany","volume":"48","author":"C Labenz","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1055\/a-0981-6484","article-title":"A 2-step fast-track elastometry service for advanced workup of nonalcoholic fatty\n          liver disease (NAFLD) patients - single-center real-world experience of outpatient\n          clinical practice","volume":"57","author":"M Alsenbesy","year":"2019","journal-title":"Z Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.cgh.2020.06.064","article-title":"Real-World Burden of Nonalcoholic Steatohepatitis","volume":"19","author":"A Geier","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"100168","DOI":"10.1016\/j.jhepr.2020.100168","article-title":"The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large\n          heterogeneity in NAFLD care","volume":"2","author":"WP Hofmann","year":"2020","journal-title":"JHEP Rep"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1055\/s-0035-1553193","article-title":"S2k Guideline non-alcoholic fatty liver disease","volume":"60","author":"E Roeb","year":"2022","journal-title":"Z Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.3748\/wjg.v27.i35.5803.","article-title":"Screening for nonalcoholic fatty liver disease-when, who and how?","volume":"27","author":"CG Dietrich","year":"2021","journal-title":"World J Gastroenterol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1194\/jlr.P067454","article-title":"NAFLD Clinical Study Group. Combined effects of the PNPLA3 rs738409, TM6SF2\n          rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based\n          study","volume":"58","author":"M Krawczyk","year":"2017","journal-title":"J Lipid Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with\n          non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective\n          derivation and global validation study","volume":"5","author":"PN Newsome","year":"2020","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the\n          general population","volume":"6","author":"G Bedogni","year":"2006","journal-title":"BMS Gastroenterology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease:\n          Systematic review and meta-analysis","volume":"65","author":"PS Dulai","year":"2017","journal-title":"Hepatology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"100477","DOI":"10.1016\/j.jhepr.2022.100477.","article-title":"Metabolic signatures across the full spectrum of non-alcoholic fatty liver\n          disease","volume":"4","author":"AJ McGlinchey","year":"2022","journal-title":"JHEP Rep"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1111\/liv.14898","article-title":"Definite and indeterminate nonalcoholic steatohepatitis share similar clinical\n          features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty\n          liver disease subjects","volume":"41","author":"J Ampuero","year":"2021","journal-title":"Liver Int"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cct.2017.07.015","article-title":"Design and rationale for a real-world observational cohort of patients with\n          nonalcoholic fatty liver disease: The TARGET-NASH study","volume":"61","author":"AS Barritt  4th","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"106175","DOI":"10.1016\/j.cct.2020.106175.","article-title":"The European NAFLD Registry: A real-world longitudinal cohort study of\n          nonalcoholic fatty liver disease","volume":"98","author":"T Hardy","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.27981","article-title":"Presence of diabetes mellitus and steatosis is associated with liver stiffness in\n          a general population: The Rotterdam study","volume":"63","author":"EM Koehler","year":"2016","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","article-title":"Risk of diabetes-associated diseases in subgroups of patients with recent-onset\n          diabetes: a 5-year follow-up study","volume":"7","author":"OP Zaharia","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic\n          syndrome","volume":"2","author":"H Yki-J\u00e4rvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"03","key":"ref26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A\n          meta-analysis","volume":"65","author":"G Targher","year":"2016","journal-title":"J Hepatol"},{"issue":"02","key":"ref27","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/hep.23727","article-title":"High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a\n          double-blind, randomized, placebo-controlled trial","volume":"52","author":"UF Leuschner","year":"2010","journal-title":"Hepatology"},{"issue":"05","key":"ref28","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jhep.2010.08.030","article-title":"A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic\n          steatohepatitis","volume":"54","author":"V Ratziu","year":"2011","journal-title":"J Hepatol"},{"issue":"12","key":"ref29","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic\n          Steatohepatitis","volume":"384","author":"PN Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/hep.32244","article-title":"Effect of diabetes medications and glycemic control on risk of hepatocellular\n          cancer in patients with nonalcoholic fatty liver disease","volume":"75","author":"JR Kramer","year":"2022","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with\n          NAFLD: an individual patient data meta-analysis","volume":"71","author":"FE M\u00f3zes","year":"2022","journal-title":"Gut"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1986-7676.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T07:58:05Z","timestamp":1676447885000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1986-7676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":30,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2023,1,9]]},"published-print":{"date-parts":[[2023,1]]}},"URL":"http:\/\/dx.doi.org\/10.1055\/a-1986-7676","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":["Gastroenterology"],"published":{"date-parts":[[2023,1]]}}}